Skip to main content
Premium Trial:

Request an Annual Quote

Silence Posts Increased 1H 2010 Loss on Intradigm Merger Costs

Premium

Silence Therapeutics this week reported its financial results for the first half of 2010, posting a sharp rise in its net loss as expenses climbed on its acquisition of Intradigm.

For the six-month period ended June 30, Silence's net loss rose to ₤7.05 million ($11 million) from ₤3.57 million in the year-ago period.

The company's revenues slipped to ₤716,000 from ₤856,000, while research and development spending climbed to ₤4.4 million from ₤2.6 million on costs associated with the Intradigm merger (GSN 4/15/2010).

At the end of June, Silence had cash and cash equivalents totaling ₤7.4 million.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.